Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1355770 | 1.00 | KCNH2 (0.52) | KCNH2CHRNB2CHRNA7CHRNA4LTA4H | |
| SCHEMBL1827493 | 0.85 | LTA4H (0.51) | KCNH2CHRNB2CHRNA7CHRNA4LTA4H | |
| SCHEMBL18616367 | 0.83 | CHRNB2 (0.41) | KCNH2CHRNB2CHRNA7CHRNA4L3MBTL1 | |
| SCHEMBL31494212 | 0.83 | MEN1 (0.61) | CHRNB2CHRNA7CHRNA4L3MBTL1MEN1 | |
| SCHEMBL6178879 | 0.83 | MEN1 (0.61) | CHRNB2CHRNA7CHRNA4L3MBTL1MEN1 | |
| SCHEMBL2808985 | 0.83 | MEN1 (0.61) | CHRNB2CHRNA7CHRNA4L3MBTL1MEN1 | |
| SCHEMBL24310072 | 0.81 | KCNH2 (0.57) | KCNH2 | |
| SCHEMBL30748884 | 0.81 | LTA4H (0.57) | KCNH2CHRNB2CHRNA7CHRNA4LTA4H | |
| SCHEMBL21232 | 0.79 | CHRNB2 (0.63) | CHRNB2CHRNA7CHRNA4L3MBTL1MEN1 | |
| SCHEMBL167264 | 0.79 | CHRNB2 (0.63) | CHRNB2CHRNA7CHRNA4L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338440-B2 | Inhibitors of IAP | NOVARTIS AG | 2012-12-25 | — | — | US | disclosed |
| US-8338440-B2 | Inhibitors of IAP | NOVARTIS AG | 2012-12-25 | — | — | US | disclosed |
| US-8338440-B2 | Inhibitors of IAP | NOVARTIS AG | 2012-12-25 | — | — | US | disclosed |
| EP-2253614-B1 | Inhibitors of IAP | NOVARTIS AG (CH) | 2012-09-19 | — | — | EP | disclosed |
| EP-2253614-B1 | Inhibitors of IAP | NOVARTIS AG (CH) | 2012-09-19 | — | — | EP | disclosed |
| EP-1735307-B1 | INHIBITORS OF IAP | NOVARTIS AG (CH) | 2012-08-29 | — | — | EP | disclosed |
| US-20120207769-A1 | Inhibitors of IAP | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120207769-A1 | Inhibitors of IAP | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120207769-A1 | Inhibitors of IAP | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-8207183-B2 | Inhibitors of IAP | NOVARTIS AG (CH) | 2012-06-26 | — | — | US | disclosed |
| EP-2065368-A1 | Inhibitors of IAP | Novartis Ag (CH) | 2009-06-03 | — | — | EP | disclosed |
| US-20080242658-A1 | Inhibitors of Iap | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-20080242658-A1 | Inhibitors of Iap | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-20080242658-A1 | Inhibitors of Iap | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-7419975-B2 | Organic compounds | NOVARTIS AG (CH) | 2008-09-02 | — | — | US | disclosed |
| US-7419975-B2 | Organic compounds | NOVARTIS AG (CH) | 2008-09-02 | — | — | US | disclosed |
| US-7419975-B2 | Organic compounds | NOVARTIS AG (CH) | 2008-09-02 | — | — | US | disclosed |
| EP-1735307-A1 | INHIBITORS OF IAP | Novartis AG (CH) | 2006-12-27 | — | — | EP | disclosed |
| US-20050234042-A1 | Organic compounds | PALERMO MARK G | 2005-10-20 | — | — | US | disclosed |
| WO-2005097791-A1 | INHIBITORS OF IAP | NOVARTIS AG (CH) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242658-A1 | Inhibitors of Iap | XIAP, BIRC2, BIRC5 | KCNH2 4393/4885CHRNB2 3586/4885CHRNA7 4152/4885 |
| US-20050234042-A1 | Organic compounds | AIFM1, BAX, API5 | KCNH2 4215/4885CHRNB2 4287/4885CHRNA7 4619/4885 |
| US-20120207769-A1 | Inhibitors of IAP | BIRC7, BIRC2, BIRC5 | KCNH2 4250/4885CHRNB2 3749/4885CHRNA7 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.